Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $78.59 USD
Change Today -1.20 / -1.50%
Volume 678.5K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals Amends Distribution, Commercialization Deal with Sandoz Inc

Anacor Pharmaceuticals announced that it has amendment to its distribution and commercialization agreement with Sandoz Inc., a Novartis (NVS) company, under which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN (tavaborole) topical solution, 5%, in the U.S. KERYDIN (tavaborole) is an antifungal topical solution used to treat a fungal infection of the toenail called onychomycosis.

Anacor Pharmaceuticals, Inc. Appoints Graeme Bell as New Executive Vice President and Chief Financial Officer Succeeding Geoffrey M. Parker

Anacor Pharmaceuticals, Inc. announced that Graeme Bell will join the company as its new Executive Vice President and Chief Financial Officer. Mr. Bell has more than 20 years of global financial experience in the pharmaceutical industry, and will succeed Geoffrey M. Parker effective as of June 1, 2015. Mr. Parker will remain with the company as a consultant to support the transition. Mr. Bell joins Anacor from Merck & Co., Inc., where he served since 2010 as its Vice President, Country CFO, U.S. Human Health, responsible for the financial oversight and support of Merck’s U.S. pharmaceutical and vaccine business.

Anacor Pharmaceuticals, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 03:20 PM

Anacor Pharmaceuticals, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 03:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Paul L. Berns, Chairman, Chief Executive Officer and President.

Anacor Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:00 PM

Anacor Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Paul L. Berns, Chairman, Chief Executive Officer and President.

Anacor Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Anacor Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $15,264,000 compared to $4,158,000 a year ago. Loss from operations was $11,796,000 compared to $20,105,000 a year ago. Net loss was $12,961,000 or $0.30 per basic and diluted share compared to $21,172,000 or $0.51 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $78.59 USD -1.20

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 107.4x
Price/Book 47.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 100.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.